181 related articles for article (PubMed ID: 30009185)
21. The clinical and immunological significance of GAD-specific autoantibody and T-cell responses in type 1 diabetes.
Boettler T; Pagni PP; Jaffe R; Cheng Y; Zerhouni P; von Herrath M
J Autoimmun; 2013 Aug; 44():40-8. PubMed ID: 23770292
[TBL] [Abstract][Full Text] [Related]
22. GAD autoantibody affinity in adult patients with latent autoimmune diabetes, the study participants of a GAD65 vaccination trial.
Krause S; Landherr U; Agardh CD; Hausmann S; Link K; Hansen JM; Lynch KF; Powell M; Furmaniak J; Rees-Smith B; Bonifacio E; Ziegler AG; Lernmark A; Achenbach P
Diabetes Care; 2014 Jun; 37(6):1675-80. PubMed ID: 24598244
[TBL] [Abstract][Full Text] [Related]
23. Combined vitamin D, ibuprofen and glutamic acid decarboxylase-alum treatment in recent onset Type I diabetes: lessons from the DIABGAD randomized pilot trial.
Ludvigsson J; Routray I; Elluru S; Leanderson P; Larsson HE; Rathsman B; Hanås R; Carlsson A; Ek T; Samuelsson U; Torbjörnsdotter T; Åman J; Örtqvist E; Badwal K; Beam C; Casas R
Future Sci OA; 2020 Jun; 6(7):FSO604. PubMed ID: 32802401
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of autoantigen-specific therapy with 2 doses of alum-formulated glutamate decarboxylase in children with multiple islet autoantibodies and risk for type 1 diabetes: A randomized clinical trial.
Elding Larsson H; Lundgren M; Jonsdottir B; Cuthbertson D; Krischer J;
Pediatr Diabetes; 2018 May; 19(3):410-419. PubMed ID: 29171140
[TBL] [Abstract][Full Text] [Related]
25. GAD-specific T cells are induced by GAD-alum treatment in Type-1 diabetes patients.
Pihl M; Barcenilla H; Axelsson S; Chéramy M; Åkerman L; Johansson I; Ludvigsson J; Casas R
Clin Immunol; 2017 Mar; 176():114-121. PubMed ID: 28131926
[TBL] [Abstract][Full Text] [Related]
26. GAD treatment and insulin secretion in recent-onset type 1 diabetes.
Ludvigsson J; Faresjö M; Hjorth M; Axelsson S; Chéramy M; Pihl M; Vaarala O; Forsander G; Ivarsson S; Johansson C; Lindh A; Nilsson NO; Aman J; Ortqvist E; Zerhouni P; Casas R
N Engl J Med; 2008 Oct; 359(18):1909-20. PubMed ID: 18843118
[TBL] [Abstract][Full Text] [Related]
27. Long-Term GAD-alum Treatment Effect on Different T-Cell Subpopulations in Healthy Children Positive for Multiple Beta Cell Autoantibodies.
Salami F; Spiliopoulos L; Maziarz M; Lundgren M; Brundin C; Bennet R; Hillman M; Törn C; Elding Larsson H
J Immunol Res; 2022; 2022():3532685. PubMed ID: 35664355
[TBL] [Abstract][Full Text] [Related]
28. GAD-treatment of children and adolescents with recent-onset type 1 diabetes preserves residual insulin secretion after 30 months.
Ludvigsson J; Chéramy M; Axelsson S; Pihl M; Akerman L; Casas R;
Diabetes Metab Res Rev; 2014 Jul; 30(5):405-14. PubMed ID: 24302596
[TBL] [Abstract][Full Text] [Related]
29. Decreased GAD(65)-specific Th1/Tc1 phenotype in children with Type 1 diabetes treated with GAD-alum.
Axelsson S; Hjorth M; Ludvigsson J; Casas R
Diabet Med; 2012 Oct; 29(10):1272-8. PubMed ID: 22587593
[TBL] [Abstract][Full Text] [Related]
30. Switch from a dominant Th1-associated immune profile during the pre-diabetic phase in favour of a temporary increase of a Th3-associated and inflammatory immune profile at the onset of type 1 diabetes.
Ryden A; Stechova K; Durilova M; Faresjö M
Diabetes Metab Res Rev; 2009 May; 25(4):335-43. PubMed ID: 19382103
[TBL] [Abstract][Full Text] [Related]
31. Human mesenchymal stem cells modulate cellular immune response to islet antigen glutamic acid decarboxylase in type 1 diabetes.
Zanone MM; Favaro E; Miceli I; Grassi G; Camussi E; Caorsi C; Amoroso A; Giovarelli M; Perin PC; Camussi G
J Clin Endocrinol Metab; 2010 Aug; 95(8):3788-97. PubMed ID: 20466784
[TBL] [Abstract][Full Text] [Related]
32. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial.
Ludvigsson J; Hjorth M; Chéramy M; Axelsson S; Pihl M; Forsander G; Nilsson NÖ; Samuelsson BO; Wood T; Aman J; Ortqvist E; Casas R
Diabetologia; 2011 Mar; 54(3):634-40. PubMed ID: 21116604
[TBL] [Abstract][Full Text] [Related]
33. GAD-alum immunotherapy in Type 1 diabetes mellitus.
Morales AE; Thrailkill KM
Immunotherapy; 2011 Mar; 3(3):323-32. PubMed ID: 21395375
[TBL] [Abstract][Full Text] [Related]
34. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.
Ludvigsson J; Krisky D; Casas R; Battelino T; Castaño L; Greening J; Kordonouri O; Otonkoski T; Pozzilli P; Robert JJ; Veeze HJ; Palmer J; Samuelsson U; Elding Larsson H; Åman J; Kärdell G; Neiderud Helsingborg J; Lundström G; Albinsson E; Carlsson A; Nordvall M; Fors H; Arvidsson CG; Edvardson S; Hanås R; Larsson K; Rathsman B; Forsgren H; Desaix H; Forsander G; Nilsson NÖ; Åkesson CG; Keskinen P; Veijola R; Talvitie T; Raile K; Kapellen T; Burger W; Neu A; Engelsberger I; Heidtmann B; Bechtold S; Leslie D; Chiarelli F; Cicognani A; Chiumello G; Cerutti F; Zuccotti GV; Gomez Gila A; Rica I; Barrio R; Clemente M; López Garcia MJ; Rodriguez M; Gonzalez I; Lopez JP; Oyarzabal M; Reeser HM; Nuboer R; Stouthart P; Bratina N; Bratanic N; de Kerdanet M; Weill J; Ser N; Barat P; Bertrand AM; Carel JC; Reynaud R; Coutant R; Baron S
N Engl J Med; 2012 Feb; 366(5):433-42. PubMed ID: 22296077
[TBL] [Abstract][Full Text] [Related]
35. Progression to type 1 diabetes is associated with a change in the immunoglobulin isotype profile of autoantibodies to glutamic acid decarboxylase (GAD65). Childhood Diabetes in Finland Study Group.
Petersen JS; Kulmala P; Clausen JT; Knip M; Dyrberg T
Clin Immunol; 1999 Feb; 90(2):276-81. PubMed ID: 10080840
[TBL] [Abstract][Full Text] [Related]
36. Exposure to exogenous insulin promotes IgG1 and the T-helper 2-associated IgG4 responses to insulin but not to other islet autoantigens.
Füchtenbusch M; Kredel K; Bonifacio E; Schnell O; Ziegler AG
Diabetes; 2000 Jun; 49(6):918-25. PubMed ID: 10866043
[TBL] [Abstract][Full Text] [Related]
37. IgG1 is the dominant subclass of antibody against glutamic acid decarboxylase among type 1 diabetes in Japanese.
Kasuga A; Shimada A; Ozawa Y; Maruyama T; Oya K; Saruta T
Endocr J; 2000 Feb; 47(1):57-62. PubMed ID: 10811294
[TBL] [Abstract][Full Text] [Related]
38. Nicotinamide reduces high secretion of IFN-gamma in high-risk relatives even though it does not prevent type 1 diabetes.
Hedman M; Ludvigsson J; Faresjö MK
J Interferon Cytokine Res; 2006 Apr; 26(4):207-13. PubMed ID: 16704296
[TBL] [Abstract][Full Text] [Related]
39. DNA vaccination encoding glutamic acid decarboxylase can enhance insulitis and diabetes in correlation with a specific Th2/3 CD4 T cell response in non-obese diabetic mice.
Gauvrit A; Debailleul M; Vu AT; Sai P; Bach JM
Clin Exp Immunol; 2004 Aug; 137(2):253-62. PubMed ID: 15270841
[TBL] [Abstract][Full Text] [Related]
40. Immune responses to glutamic acid decarboxylase and insulin in patients with gestational diabetes.
Füchtenbusch M; Bonifacio E; Lampasona V; Knopff A; Ziegler AG
Clin Exp Immunol; 2004 Feb; 135(2):318-21. PubMed ID: 14738462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
